Overview

NOS Life Sciences is committed to the development of solutions to improve the quality of life of patients suffering chronic conditions with highly specific and relevant unmet needs.

Our focus is firstly addressed to Parkinson’s, a progressive neurodegenerative condition affecting 13.1 M patients, causing an economic burden of $120 B, figures that the WHO estimates to double by 2040.

overview

To face our mission, we have developed a technology platform that combines:

  • Extensive breakthrough research on neuro-signaling molecules, and
  • Proprietary liposomal nano-delivery system for oral administration.

Therapeutic Focus

Lipea™, the first product in our pipeline, addresses the control of Parkinson’s motor dysfunctions and the modulation of the neuro-degenerative process.

Lipea™ has the potential to:

  • Slow down Parkinson’s disease progresion by 79%;
  • Enhance current tretament motor functions by 100%;
  • Reduce dyskinesia by 48%,
    as demonstrated in pre-clinicals trials.

Pipeline

Our pre-clinical results with new molecules and drug delivery systems demonstrate their potential in major neurodegenerative and inflammatory diseases that present important unmet needs.

NameConditionIndicationStage
Lipea™Parkinson's
Disease
Anti-dyskineticPre-clinical
Lipea™Parkinson's
Disease
Neuro-protectivePre-clinical
NOS1244Chron’s Disease
& Ulcerative Colitis
Reduces inflammation, lesions and painPre-clinical
NOS1367Brain Ischemia
(including perinatal)
Neuro-protectivePre-clinical

Team

A world-class team with:

  • 25-year background in the study of neurodegenerative diseases and their pharmacology.
  • 12-year experience bio-enginering and manufacturing nano-encapsulated formulations for oral administration.
  • Relevant experience in the pharmaceutical industry and entrepreneurship.
Pablo-Inones

Pablo Inones

CEO

Fernando-Fonseca

Fernando Rodríguez de Fonseca, MD, PhD

Medical Research

Tina Garyantes

Tina Garyantes, PhD

Drug Development

Ruben Henriquez

Rubén Henriquez Pelaez, PhD

Operations

Alcides Nicastro

Alcides Nicastro, PhD

Bio-Engineering

Lanciego

José Luis Lanciego, MD, PhD

Pre-Clinical Research

Torres

Rafael de la Torre Fornell, PhD

Pharmacology

Andy Maier

Andy Maier

Marketing & Communications

Strategic Partners

Untitled-1
Intelecitum
Bioexpert
Capital-Cell
Inveniam (2)

Careers

Be part of a world-class team devoted to finding solutions for Neurodegenerative Diseases.

Contact Us

1241 Canary Island Dr.,
Weston, FL, United States of América

Av. Carlos Haya 75. 2-A. 29010 Málaga, Spain

Copyright © 2018 NOS Life Sciences Corp. – All rights reserved.